Muhamed Baljevic, MD
Assistant Professor, Internal Medicine
Division of Oncology & Hematology
Academic office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840
Main Academic Ph. 402-559-8500
New Patient Ph. 402-559-5600
Fellowship: Hematology/Oncology, University of Texas MD Anderson Cancer Center, (2016)
Residency: New York-Presbyterian Hospital, Weill Cornell Medical Center, (2013)
Internship: New York-Presbyterian Hospital, Weill Cornell Medical Center, (2011)
MD, Hons Research: Weill Cornell Medical College in Qatar, (2010)
Graduate Scientist: Ansary Center for Stem Cell Therapeutics, Weill Cornell Medical College of Cornell University, (2008)
Pre-Medical Program: Weill Cornell Medical College in Qatar, (2005)
Clinical trial development of immunotherapy and novel treatment options for Multiple Myeloma, Amyloidosis and other plasma cell dyscrasias. Stem cell transplantation for multiple myeloma. Acute, chronic, myeloproliferative and myelodysplastic disorders of the bone marrow.
Dr. Baljevic is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Internal Medicine at UNMC. He moved to Doha, Qatar on an academic scholarship in 2001 where he completed secondary, undergraduate and medical education. He was the first student of the Qatar campus to take a year off medical studies to perform medical research, having worked at the Ansary Center for Stem Cell Therapeutics at the Weill Cornell Medical College in New York. Parallel to his fellowship, he also pursued a masters degree in Clinical and Translational Research at the Graduate School of Biomedical Sciences, University of Texas. He has been a recipient of several scholarships, honors and awards, most recently the 2014 Celgene Future Leaders in Hematology Award for Clinical Research, and the 2015 ASCO/AACR Workshop on Methods in Clinical Cancer Research. He has contributed to publications in prestigious journals including Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Circulation Research, Hematology/Oncology Clinics of North America, as well as several chapters by invitation.
Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Mar 23. doi: 10.1007/s00277-017-2980-3.
Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS. Telomere Length Recovery a Strong Predictor of Overall Survival In Acute Promyelocytic Leukemia. Acta Haematol. 2016 Sep 16;136(4):210-218.
Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman MS, Paietta E, Cimmino L, Aifantis J, Steidl U, Mason C, Melnick A, Levine RS. Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. Cancer Cell. 2015. Apr 13;27(4):502-15.
Hashemi-Sadraei N, Vejpongsa P, Baljevic M, Chen L Idowu M. Epstein-Barr virus related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting. Case Rep Hematol. 2015;2015:491567.
Baljevic M, Abdel-Wahab O, Rampal R, Maslak PG, Klimek VM, Rosenblat TL, Douer D, Levine RL, Tallman MS. Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. Acta Haematol. 2013;129(1):48-54.
Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am. 2011 Dec;25(6):1215-33.
Baljevic M and Pablo del Pozo R. Ethics of medical care for body packers (drug smugglers): untangling a web of fears and conflicts of interest. East Mediterr Health J. 2011 Jul;17(7):624-9.
Shmelkov S, Hormigo A, Jing D, Bath K, Proenca C, Milde T, Shmelkov E, Kushner J, Baljevic M, Murphy A, Valenzuela D, Gale N, Thurston G, Yancopoulos G, Ninan I, Lee F and Rafii S. Targeted inactivation of Slitrk5 leads to obsessive-compulsive disorder-like behaviors. Nat Med. 2010 May;16(5):598-602, 1p following 602.
Baljevic M, Lis R, Gehani A.A, Rafii A. Stem Cells in Therapeutic Medicine. Qatar Medical Journal, 2009. Dec. Vol 18/No.1.
Hooper AT, Shmelkov SV, Gupta S, Milde T, Bambino K, Gillen K, Goetz M, Chavala S, Baljevic M, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Vahdat L, Evans T, Rafii S. Angiomodulin Is a Specific Marker of Vasculature and Regulates Vascular Endothelial Growth Factor-A-Dependent Neoangiogenesis. Circ Res. 2009; 105:201-208.
Baljevic M, Sadiq N, Hussain N. "Body Packing" and its implications in Qatar. Qatar Medical Journal, 2008 Dec. Vol 17/No.2.
Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T, Clair R, Baljevic M, White I, Jin D, Chadburn A, Murphy A, Valenzuela D, Gale N, Thurston G, D. Yancopoulos, D’Angelica M, Kemeny N, Lyden D and Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumors. J Clin Invest. 2008. Jun;118(6):2021 (cover publication).
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed